May 13, 2020 / 9:02 PM / 18 days ago

BRIEF-Tracon Pharmaceuticals Reports First Quarter Results

May 13 (Reuters) - TRACON Pharmaceuticals Inc:

* TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* TRACON PHARMACEUTICALS - EXPECTS TO INITIATE DOSING OF ENVASARC IN SECOND HALF OF 2020, PROVIDE INTERIM CLINICAL TRIAL DATA IN 2021

* TRACON PHARMA - EXPECTS ENVASARC FINAL CLINICAL TRIAL DATA IN 2022, & PROVIDED DRUG IS APPROVED BY FDA, COMMERCIALIZE ENVAFOLIMAB IN 2023

* TRACON PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.78 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below